Published in final edited form as:

Fertil Steril. 2012 January ; 97(1): 134–40.e1. doi:10.1016/j.fertnstert.2011.10.040.

Assessing The Impact Of Cancer Therapies On Ovarian Reserve

Clarisa R. Gracia, MD, MSCE^{1,3}, Mary D. Sammel, ScD⁴, Ellen Freeman, PhD^{1,2}, Maureen Prewitt, RN^{1,7}, Claire Carlson, RN⁶, Anushree Ray⁷, Ashley Vance⁷, and Jill P. Ginsberg, MD^{6,8}

¹Departments of Obstetrics/Gynecology University of Pennsylvania School of Medicine

²Departments of Psychiatry University of Pennsylvania School of Medicine

³Division of Reproductive Endocrinology and Infertility University of Pennsylvania School of Medicine

⁴Biostatistics and Epidemiology and Center for Clinical Epidemiology University of Pennsylvania School of Medicine

⁵Center for Research in Reproduction and Women's Health University of Pennsylvania School of Medicine

⁶Division of Pediatric Oncology, Children's Hospital of Philadelphia University of Pennsylvania School of Medicine

⁷Center for Research in Reproduction and Women's Health University of Pennsylvania School of Medicine

⁸University of Pennsylvania School of Medicine

Abstract

Objective—To determine whether measures of ovarian reserve differ between females exposed to cancer therapies in a dose-dependent manner as compared to healthy controls of similar age and late-reproductive age.

Design—Cross-sectional analysis of data from a prospective cohort study

Setting—University Medical Center

Patients—71 cancer survivors age 15-39; 67 healthy, similarly aged unexposed subjects; 69 regularly menstruating women of late-reproductive age (40-52 years).

© 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Corresponding Author: Clarisa R. Gracia, MD, MSCE 3701 Market Street Suite 800 Philadelphia, PA 19104 Tel: 215-662-2963 Fax: 215-349-5512 cgracia@obgyn.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors have no conflicts of interest.

Capsule: Measures of ovarian reserve are impaired among cancer survivors compared to unexposed females of similar age. The degree of impairment is dependent on the toxicity of the previous treatment.

[ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01143844) identifier: NCT01143844

Interventions: None

Main Outcome measures—Early follicular phase hormones (FSH, Estradiol, Inhibin B, AMH) and ovarian ultrasound measurements (ovarian volume and Antral Follicle Counts) were compared using multivariable linear regression.

Results—In adjusted models, FSH, AMH and AFC differed between exposed vs. unexposed (FSH 11.12mIU/ml vs. 7.25mIU/ml, $p=0.001$; AMH 0.81ng/ml vs. 2.85ng/ml, $p<0.001$; AFC: 14.55 vs. 27.20, $p<0.001$). In participants with an FSH <10 , survivors had lower levels of AMH and AFC compared to controls. Alkylating agent dose score was associated with increased levels of FSH ($p=0.016$) and decreased levels of AMH ($p=0.003$). Exposure to pelvic radiation was associated with impairment in FSH, AMH, AFC and ovarian volume. AMH was similar in women previously exposed to high-dose cancer therapy and 40-42 year old controls.

Conclusions—Measures of ovarian reserve are impaired in a dose-dependent manner among cancer survivors compared to unexposed females of similar age. Reproductive hormone levels in menstruating survivors exposed to high-dose therapy are similar to late-reproductive women. The predictive value of measures for pregnancy and menopause must be studied.

Keywords

ovarian reserve; Anti-Mullerian hormone; inhibin; cancer; fertility; oncofertility

Introduction

While advancements in cancer therapies have led to improvements in long-term survival (1, 2), treatments often lead to infertility and premature ovarian failure (3). The risk of ovarian failure appears to be dependent on the dose of alkylating agent and pelvic radiotherapy received (4-9). However, it is difficult to predict the extent to which reproductive dysfunction will occur. Limited data exists assessing the utility of hormone and ultrasound measures of ovarian reserve in cancer survivors (10-12) and no study has made correlates to the physiologic changes that occur with natural reproductive aging (13-19). Early detection and a better understanding of ovarian function in cancer survivors would facilitate patient counseling about reproductive risks and fertility options.

The aim of this study was to compare measures of ovarian reserve in young cancer survivors to unexposed females of similar age, and to a cohort of late reproductive age women. We hypothesized that ovarian reserve is impaired in a dose-dependent fashion in subjects exposed to cancer therapies compared to similarly aged unexposed participants, and that subjects exposed to high-dose treatment have measures that approximate those of late reproductive age women.

Subjects and Methods

This study is part of an ongoing prospective cohort study at the University of Pennsylvania (Penn) comparing annual measures of ovarian reserve between females exposed to chemotherapy and similar age healthy unexposed females. This report compares measures of

ovarian reserve from the first assessment to a population-based cohort of late-reproductive age women (14).

Subjects

Reproductive age cancer survivors—Subjects were principally recruited from the Children's Hospital of Philadelphia Survivorship Program and the Transition Program at Penn's Living Well After Cancer Survivorship Program during the years 2006-2010. Inclusion criteria were: 1) chemotherapy treatment; 2) at least 1 year from cancer treatment with no evidence of disease; 3) age 15-39 years; 4) post-menarchal; 5) presence of uterus and both ovaries. Exclusion criteria included: history of a brain or ovarian tumor, pregnancy or lactation within three months, hormonal contraception or HT within 4 weeks, and any medical condition other than cancer associated with ovarian dysfunction.

Reproductive age controls—Unexposed controls of similar age to cancer survivors were identified through health practices affiliated with Penn and advertising. Controls were postmenarchal, with regular menstrual cycles (21-35 days), a uterus and both ovaries. Exclusion criteria were the same as for survivors.

The IRB approved this study and informed consent was obtained from all participants. Study visits occurred days 1-4 of the menstrual cycle. Subjects stopped exogenous hormones for at least 4 weeks and were seen during the subsequent menstrual cycle. Cancer survivors with irregular cycles or no menses for 6 weeks after stopping hormones were seen anytime.

Questionnaires

During a structured interview, detailed information was collected regarding demographics, medical history, menstrual characteristics, pregnancies, infertility history, contraception, medications, and substance use.

Menstrual Data—Subjects were given a menstrual diary and provided the dates of the 2 most recent menstrual cycles during the interview. Cycle length was calculated as the interval between the 2 most recent menstrual cycles. Women were categorized as having regular menstrual cycles if they reported regular menses (21-35 days) and no hormone use the previous year.

Physical Examination—Height and weight were measured for calculating BMI.

Pelvic Ultrasonography—Uterine volume, ovarian volume and antral follicle counts (AFC) were determined by ultrasonography. Measurements were performed using a Siemens Sonoline G50 machine, 6.8 MHz probe. Transvaginal ultrasonography was preferred, though transabdominal ultrasound was performed in participants uncomfortable with the transvaginal approach. Uterine and ovarian volumes were calculated using the ellipse formula ($A \times B \times C \times 0.5233$) (33). AFC was determined for subjects undergoing transvaginal ultrasonography when both ovaries were visualized, and was defined as the number of follicles between 2-10 mm in average diameter. Numbers of small (2-5mm follicles) and large antral follicles (5-10mm) were recorded.

Hormone analysis—Serum hormones were measured at Penn's Clinical Translational Research Center using FSH and estradiol Coat-A-Count kits (Diagnostic Products Corporation, Los Angeles, CA) and inhibin B and AMH ELISA kits (Diagnostic Systems, Webster TX). FSH IRMA assay's range is 1.5–100mIU/ml, sensitivity of 0.7 mIU/ml, inter-assay and intra-assay coefficients of variation (cov) <6 % and 4 % respectively. Estradiol RIA assay's range is 20–3600pg/ml, sensitivity of 7pg/ml, inter-assay and intra-assay cov <8.1% and 7 % respectively. Inhibin B ELISA assay's range is 10-531pg/ml, sensitivity of 7pg/ml; inter-assay and intra-assay cov <8% and <6% respectively. AMH ELISA assay's range is 0.050-10.0ng/ml, sensitivity of 0.025ng/ml, inter-assay and intra-assay cov <8% and 5%.

Cancer Therapy—Exposure data were obtained by abstracting medical records. Treatment was summarized for chemotherapeutic type, duration, cumulative dose; radiation dose and location; type of bone marrow transplantation (BMT); and surgery. Chemotherapies categorized as alkylating agents included: BCNU, busulfan, CCNU, chlorambucil, cyclophosphamide, ifosfamide, melphalan, nitrogen mustard, procarbazine, and thiotepa. Alkylating agent dose scores (AAD) (range 0-9) were determined by assigning a score ranging from 1 to 3 for each agent received, and summing the scores over each agent received. We utilized previously published cut-points to define the scores (20). Exposure to pelvic radiation was defined as exposure to direct pelvic radiation or total body irradiation (TBI).

Late-reproductive age women: To compare reproductive hormone measures to naturally aging women, subjects were identified from the Penn Ovarian Aging Cohort Study (POAS), a population-based longitudinal study of reproductive hormone levels over the menopausal transition (21, 22). For selection into the present study, eligibility criteria included age 40 years, regular menstrual cycles (21-35 days), the presence of a uterus and at least one ovary, and complete early follicular phase reproductive hormone assays performed by the methods described above. Women using hormonal medications, pregnant or lactating were excluded.

Data analysis

An a prior sample size calculation indicated that a total of 120 participants (60 per group) were required for this study. The sample size calculations were based on published estimated difference in mean FSH and AMH levels between subjects and controls(10), an alpha of 0.05, power of 0.80, and a 1:1 ratio of exposed to unexposed.

Log transformed hormone levels and ultrasound data were compared using multivariable linear regression models. Subgroup analyses compared measures of ovarian reserve in regularly menstruating women and among exposure groups. Pearson Chi-squared analyses or ANOVA and t-tests were performed for categorical or continuous data respectively. To correct for multiple comparisons in this analysis, a two tailed $p < 0.01$ was considered significant. Statistical analysis was performed using STATA, v10.0.

Results

Seventy-one cancer survivors and 67 similarly aged controls were included. When comparing baseline characteristics of cancer survivors enrolled in this study compared to those of the overall survivorship cohort (N=391), mean age of enrolled cancer survivors was slightly higher than those in the survivorship cohort 25.7 vs. 22.8 years, $p=0.001$) but the proportion of cancer types was similar between groups. Within the study population, twenty-four cancer survivors had been treated for lymphoma (15 Hodgkin, 9 non-Hodgkin), 23 leukemia, 10 sarcoma, 4 Wilms' tumor, 3 breast cancer, and 7 other. 63/71 (89%) received alkylators, 13/71 (18%) received pelvic radiation, and 16/71 had a history of BMT (10 with TBI). Median age at diagnosis was 11 years (4mo–29yrs). Thirty-seven (52%) were treated before menarche and 34/71 after.

Mean age of participants was 26.4 years (95%CI 25.5-27.4 yrs., range 15-39 yrs.). Mean BMI was 24.3 kg/m² (95%CI 23.4-25.2 kg/m²). Most were Caucasian (83.6%) and 92.8% graduated high school. Comparison of baseline characteristics between exposed and unexposed participants revealed similar age, BMI, and marital status. More exposed subjects were Caucasian, higher in income and less likely to smoke (Table 1). On average, study visits occurred on cycle day 3 for both groups.

Comparison of menstrual characteristics between groups revealed no difference in age at menarche (12.5 exposed vs. 12.4 unexposed, $p=0.67$). Ten survivors and 4 controls stopped exogenous hormones to participate in the study. Ninety-two percent of survivors (65/71) and all controls had spontaneous menses off hormones. Sixty-nine percent (49/71) of survivors and 94% (63/67) of controls reported regular menstrual cycles (21-35 days), with no hormone use during the past year. In those reporting regular menses, cycle length (28.8 exposed vs. 29.1 unexposed, $p=0.46$) and bleeding length (5.16 exposed vs. 4.92 unexposed, $p=0.24$) were not different.

Table 2 presents regression models of hormones and ultrasound measures. Unadjusted analyses demonstrated that cancer survivors had significantly higher FSH and lower estradiol, AMH, AFC and ovarian volume compared to unexposed. Models adjusted for age, race and BMI confirmed statistically significant associations for FSH, AMH and AFC, but not for ovarian volume (Table 2). Adjustment for potential confounders including smoking, income and education did not change estimates of association and therefore were not included in the models. AFC<5mm and AFC ≥5mm were different between groups ($P<0.001$). Overall, AFC correlated with AMH ($r=0.69$, $p=0.0001$), and the correlation was similar between small and large AFC. Treatment before or after menarche, and time since diagnosis was not associated with outcomes.

When the analysis was restricted to 49 survivors and 63 controls with regular menstrual cycles and no hormone use over the past year, FSH was higher, and Estradiol, AMH and AFC were lower in survivors compared to controls (geometric mean hormones: FSH 9.08 mIU/ml vs. 7.09 mIU/ml; $p=0.01$; Estradiol 24.08 vs. 30.28 pg/ml, $p=0.046$; AMH: 1.13 ng/ml vs. 2.81 ng/ml, $p<0.001$; AFC: 16.91 vs. 26.88, $p=0.002$). No significant differences were noted in Inhibin levels or ovarian volume between groups.

To assess the utility of AMH and AFC in women whose FSH was considered normal, we compared AMH and AFC between 45 survivors and 51 controls with FSH values <10 mIU/ml. In linear regression models adjusted for age, race and BMI, AMH and AFC were lower in survivors compared to controls (geometric mean AMH 1.67 vs. 2.96 ng/ml, $p=0.004$; AFC 18.15 vs. 27.40, $p=0.006$).

Comparison of measures of ovarian function by AAD in women without a history of pelvic radiation or TBI revealed a dose-response relationship. In models adjusted for age, race and BMI, for each unit increase in alkylator score, geometric mean FSH values increased by 0.91 mIU/ml ($p=0.016$) and geometric mean AMH levels decreased by 0.55 ng/ml ($p=0.003$) (Supplemental Figure 1a and 1b). Differences in Estradiol, Inhibin B, AFC and ovarian volume were not statistically significant.

Measures of ovarian reserve were independently associated with exposure to pelvic radiation. Adjusted comparisons of 13 cancer survivors exposed to pelvic radiotherapy (including TBI) to 58 controls revealed that FSH was higher, and AMH, AFC, ovarian and uterine volumes lower in the survivors compared to controls (geometric mean hormones: FSH 28.41 vs. 9.36 mIU/ml, $p<0.001$; AMH 0.15 vs. 1.24 ng/ml, $p<0.001$; AFC 2.94 vs. 17.46, $p=0.001$; ovarian volume 4.05 vs. 7.97 ml, $p=0.01$; uterine volume 30.04 vs. 49.31 ml, $p=0.04$).

Measures of ovarian reserve were compared between cancer survivors who had undergone BMT with TBI or BMT without TBI to those who had no history of BMT. Compared to survivors without a history of BMT, FSH, Estradiol, Inhibin B, AMH, AFC and ovarian volume were significantly impaired in survivors with a history of BMT and TBI (geometric mean hormones: FSH 40.42 vs. 9.39 mIU/ml, $p<0.001$; Estradiol 15.09 vs. 25.13 pg/ml, $p=0.04$; Inhibin B 10.61 vs. 32.92 pg/ml, $p=0.003$; AMH 0.01 vs. 1.28 ng/ml, $p<0.001$; AFC 0.71 vs. 17.78, $p<0.001$; ovarian volume 1.82 vs. 8.21 ml, $p<0.001$). Inhibin B levels were also significantly lower in women who had a BMT without TBI compared to the no BMT group (geometric mean Inhibin B 12.95 vs. 32.92 pg/ml, $p=0.03$). Six of the 10 subjects with a history of BMT and TBI reported regular menstrual cycles.

Comparison to late-reproductive age women: 69 menstruating late-reproductive aged women from the POAS met inclusion criteria. Except for race, baseline demographic characteristics (age, BMI, employment, education, smoking, alcohol use) of the 69 eligible participants were no different than the remainder of the original POAS cohort. While the POAS cohort was designed to be 50% African American, the cohort of cancer survivors was predominately Caucasian. Mean age of the late-reproductive women was 45.4 years (range 40-52 years), mean BMI was 28.67 kg/m² and 80% (55/69) subjects were Caucasian. Table 3 presents geometric mean early follicular phase hormone measures in regularly menstruating subjects by group, adjusted for BMI and race. Because of the distribution of treatment, for this analysis, high dose cancer survivors were defined as having an AAD ≥ 3 or having been exposed to pelvic radiation including TBI. Overall, FSH was higher and AMH lower in late-reproductive age women compared to unexposed reproductive age subjects. Mean levels of AMH in cancer survivors fell between those of unexposed reproductive and unexposed late-reproductive age groups.

To further compare measures between groups, adjusted geometric mean AMH levels were plotted by group and stratified by age in unexposed late-reproductive women (Figure 1). AMH in the high-dose exposure group were not significantly different from levels in women between the ages of 40-42. However, levels were significantly lower than the unexposed and low dose groups and significantly higher than the late-reproductive age group over 42 years old ($p < 0.001$).

Discussion

Recent diagnostic and therapeutic advances in oncology have led to greater survival rates in young cancer patients, but these treatments may deplete the ovarian follicular pool increasing the risk of ovarian failure and infertility. While the exact mechanism of ovarian injury is unclear, follicular apoptosis and cortical fibrosis occur (23). In women already treated for cancer, it is difficult to predict the extent to which reproductive dysfunction will occur. Early detection of compromised ovarian function in cancer survivors would be helpful in determining the window of fertility for family planning, and anticipating the need for HT for menopausal symptom management and bone health. While several hormone and ultrasound measures of ovarian reserve are used to assess natural reproductive aging and predict response and pregnancy in infertile women undergoing ART, limited data exist assessing the utility of measures of ovarian reserve in cancer survivors (11, 12, 24, 25).

In this study, a comprehensive assessment of ovarian reserve was performed in a population of reproductive age cancer survivors and similar age controls. Comparison of measures of ovarian reserve between these groups revealed significant impairment in FSH, AMH and AFC in cancer survivors. Even among cancer survivors with regular menstrual cycles or those with FSH levels considered to be in the “normal range”, AMH and AFC were significantly lower compared to unexposed females of similar age, supporting sub-clinical follicular depletion. We also noted a dose-dependent relationship between cancer therapies and measures of ovarian reserve. Specifically, cancer survivors with greater exposure to alkylators, pelvic radiotherapy, or BMT with TBI had the most impaired ovarian reserve. These findings further support the value of these measures to estimate the ovarian follicle pool and hold promise for the assessment of the fertility risk of newly developed therapeutics.

These data corroborate findings from other studies of childhood cancer survivors (10, 25, 26) indicating that FSH, AMH and AFC are abnormal in cancer survivors. In particular, our data and others suggest that AMH and AFC are very sensitive measures of diminished ovarian reserve in this population. These results differ from a recent report assessing random AMH values in a cohort of 185 survivors, where significant differences were not detected between survivors and controls. We suspect that no association was detected in that study because of the wide age range and disparity between groups. In addition, our findings with respect to inhibin B are more consistent with those of van Beek who reported that while Inhibin B levels were lower in survivors compared to controls, differences did not reach statistical significance (12, 25). Similarly, our findings and others suggest that AMH is a particularly attractive measure of ovarian reserve because levels reflect the number of preantral follicles, fluctuate minimally during the menstrual cycle (27, 28) and do not appear

to be influenced by exogenous hormones(29). Previous reports indicate that AMH levels decline with age, predict time to menopause, predict pregnancy after in vitro fertilization, and are associated with fecundity in the general population (30-36).

To better characterize the degree of oocyte depletion and estimate the “reproductive age” of cancer survivors, hormone measures were compared to a cohort of regularly menstruating late-reproductive age women. Mean levels of AMH in cancer survivors fell between those of unexposed mid-reproductive age women and unexposed late-reproductive age women. Interestingly, in stratified analyses, mid-reproductive age cancer survivors who received highly gonadotoxic therapy had AMH levels similar to women 40-42 years of age. The data presented in this report are insufficient to assess the predictive value of ovarian reserve measures, or estimate the “reproductive window” and therefore these tests should be interpreted with caution by clinicians. Hormone levels should not be used to predict spontaneous pregnancy rates or need for contraception in cancer survivors(37). However, since the reproductive window cannot be determined, appropriate candidates for pregnancy should not to delay childbearing unnecessarily.

The ability to lead full reproductive lives is very important to cancer survivors and reproductive problems can lead to substantial anxiety and negatively impact quality of life(38, 39). Measures of ovarian reserve may be useful to predict the reproductive impact of cancer therapies so that fertility preservation strategies such as embryo, oocyte and ovarian tissue cryopreservation can be targeted to those at highest risk. In addition, establishment of an effective surveillance protocol for the early detection of compromised ovarian function after cancer may allow young cancer survivors to pursue aggressive fertility treatments when there is still a reasonable chance of success.

This study has several strengths. Recall bias was minimized by prospective enrollment and valid comparisons were made to an unexposed control population of similar age. Confounding has been reduced by restricting the study to non-pregnant, non-lactating females not using hormones and without other causes of ovarian dysfunction. Unlike some studies, a comprehensive evaluation of ovarian reserve was performed and hormone variability minimized by obtaining early follicular phase measures. Cancer diagnoses and treatments were validated with medical records to diminish misclassification bias.

Several limitations should be mentioned. This report represents a cross-sectional analysis of data that cannot prove causation or assess the predictive value of measures for pregnancy and menopause. While differences in baseline characteristics of unexposed and exposed groups may indicate selection bias, this is unlikely since associations persisted in adjusted analyses. A washout period of 4 weeks after stopping exogenous hormones may be insufficient for normalization of reproductive hormones and biased the overall analysis(40). However, significant associations persisted when the analysis was restricted to regularly menstruating subjects who had not been on hormones over the past year, suggesting that hormone use was not a confounder. Typical of studies involving childhood and young adult cancer survivors, subjects with a variety of diagnoses and treatments were included. Therefore it was not possible to compare the effect of specific chemotherapeutic regimens on ovarian reserve in this study. Finally, this cohort may not be representative of the general

population of survivors. It is possible that participating subjects were more concerned about their fertility than non-participants.

Overall, measures of ovarian reserve differ between female cancer survivors and controls in a dose dependent manner, even if menstrual function is normal. AMH and AFC appear to be the most sensitive measures of ovarian reserve in this population and are helpful measures for quantifying the damage to the ovaries after cancer therapy. Longitudinal studies of cancer survivors are needed to determine whether impairment in these measures truly reflects fertility and/or predicts time to menopause. in cancer survivors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by grants from the National Institutes of Health KL1-CA-133839-01 (Gracia), National Institutes of Health R01HD062797-02 (Gracia), Oncofertility Consortium NIH 1 UL1 RR024926-01 NIH Roadmap Interdisciplinary Research Consortia, and Pfizer Scholars Grant in Clinical Epidemiology

Oral presentation at the 2008 Annual Meeting of the American Society for Reproductive Medicine. No company derived money was used for salaries for investigators or for talks. The first author was in charge of the data and wrote the paper.

Dr. Shiv Kapoor, Ph.D. performed all hormone assays for this study at the Clinical Translational Research Center, University of Pennsylvania supported by UL1RR024134 from the National Center For Research Resources.

References

1. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. *Cancer*. 2004; 101:3–27. [PubMed: 15221985]
2. Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. *BJOG*. 2002; 109:107–14. [PubMed: 11905426]
3. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. *Hum Reprod*. 1992; 7:1342–6. [PubMed: 1291557]
4. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. *J Clin Endocrinol Metab*. 2006; 91:1723–8. [PubMed: 16492690]
5. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *J Natl Cancer Inst*. 2006; 98:890. [PubMed: 16818852]
6. Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. *Crit Rev Oncol Hematol*. 1998; 28:121–8. [PubMed: 9768347]
7. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. *Fertil Steril*. 1986; 45:443–59. [PubMed: 3082680]
8. Couto-Silva AC, Trivin C, Thibaud E, Esperou H, Michon J, Brauner R. Factors affecting gonadal function after bone marrow transplantation during childhood. *Bone Marrow Transplant*. 2001; 28:67–75. [PubMed: 11498747]
9. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. *Int J Radiat Oncol Biol Phys*. 2005; 62:738–44. [PubMed: 15936554]

10. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. *Hum Reprod.* 2003; 18:2368–74. [PubMed: 14585889]
11. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. *Hum Reprod.* 2009; 24:982–90. [PubMed: 19153092]
12. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. *J Clin Endocrinol Metab.* 2003; 88:5307–14. [PubMed: 14602766]
13. Landgren BM, Collins A, Csemiczky G, Burger HG, Baksheev L, Robertson DM. Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. *J Clin Endocrinol Metab.* 2004; 89:2763–9. [PubMed: 15181055]
14. Freeman EW, Sammel MD, Gracia CR, Kapoor S, Lin H, Liu L, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. *Fertil Steril.* 2005; 83:383–92. [PubMed: 15705379]
15. Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. *J Clin Endocrinol Metab.* 1999; 84:105–11. [PubMed: 9920069]
16. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. *Fertil Steril.* 2005; 83:979–87. [PubMed: 15820810]
17. Ruess ML, Kline J, Santos R, Levin B, Timor-Tritsch I. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. *Am J Obstet Gynecol.* 1996; 174:624–7. [PubMed: 8623796]
18. Sharara FI, McClamrock HD. The effect of aging on ovarian volume measurements in infertile women. *Obstet Gynecol.* 1999; 94:57–60. [PubMed: 10389718]
19. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. *Fertil Steril.* 2003; 79:1091–100. [PubMed: 12738501]
20. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol.* 2009; 27:2677–85. [PubMed: 19364965]
21. Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. *Menopause.* 2005; 12:128–35. [PubMed: 15772558]
22. Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. *Obstet Gynecol.* 2007; 110:230–40. [PubMed: 17666595]
23. Meirrow D, Biederman H, Anderson RA, Wallace WH. Toxicity of chemotherapy and radiation on female reproduction. *Clin Obstet Gynecol.* 53:727–39. [PubMed: 21048440]
24. Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. *Hum Reprod.* 2008; 23:674–8. [PubMed: 18216040]
25. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. *J Clin Endocrinol Metab.* 2007; 92:3869–74. [PubMed: 17726078]
26. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l. *Hum Reprod.* 2003; 18:417–22. [PubMed: 12571182]
27. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. *Fertil Steril.* 2002; 77:357–62. [PubMed: 11821097]
28. Cook CL, Siow Y, Taylor S, Fallat ME. Serum mullerian-inhibiting substance levels during normal menstrual cycles. *Fertil Steril.* 2000; 73:859–61. [PubMed: 10731554]

29. Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol.* 2007; 134:196–201. [PubMed: 17335955]
30. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil Steril.* 2002; 77:468–71. [PubMed: 11872196]
31. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. *Fertil Steril.* 95:747–50. [PubMed: 21074758]
32. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, et al. Antimullerian hormone as a predictor of natural fecundability in women aged 30–42 years. *Obstet Gynecol.* 117:798–804. [PubMed: 21422850]
33. Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. *J Clin Endocrinol Metab.* 2008; 93:3478–83. [PubMed: 18593767]
34. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. *Hum Reprod.* 2002; 17:3065–71. [PubMed: 12456604]
35. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. *Fertil Steril.* 2008; 90:737–43. [PubMed: 17923131]
36. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS. Anti-Mullerian hormone (AMH): what do we still need to know? *Hum Reprod.* 2009; 24:2264–75. [PubMed: 19520713]
37. Hershlag A, Schuster MW. Return of fertility after autologous stem cell transplantation. *Fertil Steril.* 2002; 77:419–21. [PubMed: 11821109]
38. Kinahan KE, Didwania A, Nieman CL. Childhood cancer: fertility and psychosocial implications. *Cancer Treat Res.* 2007; 138:191–200. [PubMed: 18080666]
39. Schover LR. Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. *Med Pediatr Oncol.* 1999; 33:53–9. [PubMed: 10401498]
40. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JW, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. *Hum Reprod.* 25:1520–7. [PubMed: 20348556]

Figure 1.

Geometric mean early follicular phase AMH levels for regularly menstruating participants in each exposure group. From left to right: mid reproductive age unexposed subjects similar in age to cancer survivors, low dose = cancer survivors exposed to low-dose therapy, high dose = cancer survivors exposed to high-dose therapy, and unexposed late-reproductive aged women stratified by age. Confidence intervals are shown.

High Dose Defined as AAD ≥ 3 or exposure to pelvic radiation including TBI

The horizontal reference line represents mean AMH value in cancer survivors exposed to high-dose therapy.

Table 1

Baseline characteristics

	Exposed N = 71	Unexposed N = 67	P-value
Age	25.67 (24.17-27.17)	27.26 (26.10-28.43)	0.10
BMI	23.52 (22.46-24.58)	25.14 (23.74-26.53)	0.07
Race – Caucasian	86% (61/71)	72% (48/67)	<0.001
Education >HS	86% (61/71)	100% (67/67)	0.001
Income (>60K)	53% (29/55)	23% (13/56)	<0.001
Current Smoking	3.0% (2/69)	15% (10/65)	<0.001
Marital Status Single	43/66 (65%)	46/59 (78%)	0.11
Previous pregnancy	20% (14/71)	31% (20/65)	0.14
Median number of previous pregnancies* (Range)	2 (1-3)	1 (1-5)	0.64**

HS = high school graduate

* For participants who had a previous pregnancy

** Kruskal Wallace rank test

Table 2

Geometric mean (95% CI) reproductive hormone measures of ovarian reserve in cancer survivors vs. unexposed participants of similar age

	Unadjusted			Adjusted**		
	Exposed (n =71)	Unexposed (n =67)	P value	Exposed	Unexposed	P value
FSH (mIU/ml)	11.35 (9.70-13.28)	7.52 (6.39-8.85)	<0.00 1	11.12 (9.47-13.06)	7.25 (6.00-8.76)	0.001
Estradiol (pg/ml)	23.89 (20.60-27.70)	39.96 (25.73-34.90)	0.037	24.21 (20.88-28.08)	29.41 (24.73-34.97)	0.084
Inhibin B (pg/ml)	27.87 (22.42-34.63)	34.32 (27.57-42.72)	0.184	27.03 (21.72-33.65)	29.59 (22.99-38.09)	0.582
AMH (ng/ml)	0.79 (0.60-1.04)	2.74 (2.07-3.64)	<0.00 1	0.81 (0.61-1.07)	2.85 (2.06-3.96)	<0.001
Ovarian volume (ml)	7.19 (6.06-8.32)	9.04 (7.80-10.49)	0.045	7.42 (6.13-8.71)	9.29 (7.80-10.79)	0.056
AFC***	15.0 (11.71-18.35)	26.51 (22.44-30.58)	<0.00 1	14.55 (10.80-18.30)	27.20 (23.05-31.35)	<0.001

Geometric mean hormone levels shown

* Unadjusted Analysis

** Linear regression model adjusted for mean age, race, mean BMI

*** AFC results are shown for the 60 exposed and 61 unexposed participants who had transvaginal ultrasound assessment of AFC

Table 3

Comparison of reproductive hormones in unexposed reproductive age participants, cancer survivors (low and high-dose), and late-reproductive age women, restricted to regularly menstruating participants not using hormones over the past year

	Unexposed (n=63)	Low-dose Exposure (n =27)	High-dose Exposure (n =22)	Late- reproductive (n=69)
FSH (mIU/ml)	6.93 (6.09-7.89)	7.93 (6.63-9.47)	**10.60 (8.68-12.95)	*8.15 (7.19-9.23)
Estradiol (pg/ml)	31.81 (27.27-37.10)	*24.54 (19.85-30.34)	*22.95 (18.10-29.11)	37.45 (32.27-43.47)
Inhibin B (pg/ml)	39.75 (29.88-52.89)	37.90 (25.54-56.23)	30.37 (19.33-47.73)	30.70 (23.40-40.29)
AMH (ng/ml)	3.07 (2.17-4.36)	1.99 (1.23-3.24)	**0.52 (0.30-0.90)	**0.19 (0.13-0.26)

* comparison to reference unexposed group, p<0.05

** comparison to reference unexposed group, p<0.001

Geometric mean hormone levels shown

Model adjusted for mean BMI and race

High Dose Exposure defined as AAD 3 or exposure to pelvic radiation including TBI

Low Dose Exposure defined as any cancer treatment that does not meet criteria for "high dose exposure"